Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Steven Dubinett, M.D.
Steven Dubinett, M.D.

Specialty:

Pulmonary Disease

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Professor, Department of Pathology and Laboratory Medicine
Chief, Department of Medicine, Pulmonary and Critical Care Medicine
Member, ACCESS Department - Cellular and Molecular Pathology
Member, JCCC Cancer Nanotechnology Program Area
Member, JCCC Tumor Immunology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Internal Medicine, Massachusetts General Hospital, 1985 - 1987
Residency:
Internal Medicine, Veterans Administration Medical Center, 1981 - 1984
Internship:
Internal Medicine, UMDNJ - University Hospital, 1980 - 1981
Medical Degree:
M.D., University of Medicine and Dentistry of NJ, 1980

Certification(s):

Board Certification(s):
Critical Care Medicine, American Board of Internal Medicine, 1991
Pulmonary Disease, American Board of Internal Medicine, 1988
Internal Medicine, American Board of Internal Medicine, 1983

Contact Information:

Phone:
(310) 825-8061 Pulmonary and Critical Care Medicine information and referral
Email:

Scientific Interest(s):

Dr. Steven Dubinett's research encompasses several areas of translational investigation in lung cancer. The primary focus of study assesses the impact of tumor cyclooxygenase 2 (COX-2) in lung cancer. He and his colleagues are investigating COX-2-dependent gene and protein expression and determining how these modify tumor invasion, angiogenesis, immunity and apoptosis in non-small cell lung cancer (NSCLC). Identification of COX-2 dependent gene regulation will allow the researchers to define new biomarkers in the COX-2 inhibitor-mediated antitumor response. Novel genes and pathways for future targeted therapies are also being identified and studied.

Selected Cancer-Related Publications:

Cui X, Zhang L, Luo J, Rajasekaran A, Hazra S, Cacalano N, Dubinett SM. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Oncogene. 2007; 26(29): 4253-60.

Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol. 2007; 71(6): 1715-20.

Lee JM, Mao JT, Krysan K, Dubinett SM. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol. 2007; 3(2): 149-53.

Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM. EGFR Signaling is Required for TGF-{beta}1-mediated COX-2 Induction in Human Bronchial Epithelial Cells. Am J Respir Cell Mol Biol. 2007.

Lu QY, Jin YS, Zhang ZF, Le AD, Heber D, Li FP, Dubinett SM, Rao JY. Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling. Lab Invest. 2007; 87(5): 456-65.